Condition

MdDS Treatment: Mal de Débarquement Syndrome

Book a 15 min call

Free, 15 minutes. It is a clinical fit conversation, not a sales screen.

If you walked off a cruise, a flight, or a long drive weeks ago and you're still rocking — and it eases when you drive, then returns the moment you stop — that has a name: mal de débarquement syndrome. MdDS is real, formally defined, and studied; most providers have simply never seen it. MindForge provides criteria-literate evaluation and readaptation-based retraining in Dallas. Free 15-minute call · (214) 730-6463.

MindForge doesn't bill insurance — by design. Direct-pay is what makes an individualized, intensive program possible rather than care shaped by billing codes. HSA/FSA and financing options exist, and a written Good Faith Estimate precedes any commitment.

What MdDS is

Aboard a ship or plane, your brain builds an internal model of the motion — and adapts brilliantly. MdDS is that adaptation failing to release: persistent rocking, swaying, or bobbing perception lasting beyond a month after passive-motion exposure (a spontaneous-onset variant exists too), with the pathognomonic signature that re-exposure to passive motion — riding in a car — temporarily relieves it [1]. It skews strongly female, typically onsets in the 40s–50s [1], and is routinely misdiagnosed as vestibular migraine, Ménière's, or anxiety — when it's recognized at all.

That relieved-by-driving paradox deserves a sentence of its own, because it's the detail that makes many patients doubt themselves: a symptom that improves in motion sounds backwards until you understand the mechanism — and then it's practically diagnostic.

The specialist runaround

The typical MdDS path: ENT (ears normal), neurology (scans normal), cardiology (heart fine), a motion-sickness pill that does nothing — because vestibular test batteries in MdDS are characteristically normal, which is itself diagnostic information when the history fits [1]. Being cleared by everyone while still rocking is not evidence you're imagining it; it's the textbook presentation of a condition most clinics have never treated. We have — and the highly organized MdDS patient community is a large part of why patients find their way to criteria-literate care at all.

How we evaluate MdDS: the Discovery Day

The MindForge Discovery Day — comprehensive neurological evaluation + report of findings + care plan. MdDS evaluation: the structured onset-and-pattern discriminator (passive-motion onset, rocking quality, motion-relief — the history IS the backbone), symptom instruments, and the full objective battery — where documenting normal peripheral function alongside the classic history is precisely the diagnostic value [1]. Overlap screening for PPPD and vestibular migraine, which coexist and mimic. Same-day findings, written GFE, routing by name.

Treatment: the MdDS Intensive

Failed generic advice: "it'll fade on its own" (after months, it often hasn't), suppressant medications (characteristically ineffective for MdDS), or serial clearance with no plan. Counter-thesis: MdDS behaves like a maladapted internal motion model — and the published treatment lane is readaptation: retraining the vestibulo-ocular system to release the stored motion pattern. The strongest published signal comes from a readaptation-protocol research cohort (n=141, 2017 follow-up): 78% of classic-onset patients significantly improved (≥50% symptom reduction) after the treatment week, with roughly half maintaining significant improvement at one year, and earlier treatment and younger age predicting better outcomes [2]. Those are published research-cohort outcomes, not MindForge outcomes — we cite them because they define what's possible in the lane we work in: vestibular readaptation retraining (our specific protocol implementation per clinical sign-off), supported by gaze/oculomotor work, balance re-education, graded conditioning, FM support for sleep and stress physiology, and pacing.

The caveats, printed: response rates decline with chronicity; recurrence after future passive-motion exposure (travel) is documented in the same research [2]; no cure claims. Program pricing is shared on your free 15-minute call (exact quote + GFE at the wrap).

What treatment looks like: Discovery Day → a concentrated retraining week(s) → re-test and a travel-planning conversation (what to expect). MdDS is a classic traveler condition — patients fly in for exactly this.

Costs: DD = one fixed fee, shared on your call · program pricing on the same call + GFE · ways to pay. Schedule: 15-min call → Discovery Day scheduled live on your call → program typically within days.

Frequently asked questions

Is MdDS real?

Yes — formally defined (Bárány criteria, 2020 [1]), studied, and treated in a published research lane [2]. Most providers have simply never met it.

Why does driving help?

Passive motion temporarily re-engages the stored motion model — the paradox is characteristic, not contradictory.

My vestibular tests were normal — so what's wrong?

Normal peripheral tests WITH the classic history is the expected MdDS picture [1] — the pattern is the diagnosis.

Can it be cured?

Published cohorts show meaningful, durable improvement for many — alongside declining response with chronicity and documented recurrence risk [2]. We promise measurement, not cures.

Will it come back if I travel?

Recurrence after re-exposure is documented [2]; we plan travel strategy with you at re-test.

MdDS vs PPPD?

Constant rocking relieved by motion versus dizziness worsened by motion and visual complexity — see the PPPD page; they can coexist.

Do you take insurance?

We're direct-pay, with superbills provided — see ways to pay.

Sources: [1] MdDS diagnostic criteria (Cha et al., Bárány Society/J Vestib Res, 2020); epidemiology and clinical profile (Cha, 2018). [2] VOR-readaptation research lane: Dai et al., Frontiers in Neurology 2014 (initial cohort) and 2017 one-year follow-up (n=141): 78% classic-onset significant improvement post-treatment-week; ~52%/48% (classic/spontaneous) retained at 1 year; complete remission 27%/19%; earlier treatment and younger age favorable.

Updated September 24, 2026